News | Nuclear Imaging | February 14, 2020

Partnership advances innovation and increases precision of liver-directed oncology therapies for patients

SIR-Spheres Y-90 resin

SIR-Spheres Y-90 resin microspheres are released into the hepatic artery.


February 14, 2020 —  Sirtex Medical, a leading manufacturer of targeted liver cancer therapies, announced a collaboration with MIM Software Inc., a leading global provider of practical imaging solutions in the fields of radiation oncology, radiology, nuclear medicine, neuroimaging and cardiac imaging. Under the terms of the agreement, Sirtex's specialized sales teams in the United States, Europe and other key global markets will offer MIM SurePlan LiverY90 software alongside the company's SIR-Spheres Y-90 resin microspheres to improve treatment precision for patients with hepatic tumors.

MIM SurePlan LiverY90 provides timesaving tools and post-treatment dosimetry for interventional radiologists and nuclear medicine physicians treating hepatic tumors with SIR-Spheres. The software allows physicians to quickly calculate the dose delivered by the microspheres to improve treatment decisions and patient care. The technology also incorporates CT, PET, SPECT and MRI scans simultaneously to deliver results on spheres deposition, coverage and absorbed dose, allowing physicians to make informed decisions faster about next steps. 

In addition to sharing a mission to provide physicians the tools they need to treat cancers, Sirtex and MIM also share a commitment to provide patients the best care throughout the treatment journey.

"Given the overlap of their technology and our SIR-Spheres product, Sirtex and MIM have a long history of working alongside clinical care teams," said Kevin Smith, chief executive officer of Sirtex. "Now as partners, we will be able to combine our expertise and resources to provide an even higher level of support to treat liver tumors. We are excited to see how this collaboration will benefit physicians and ultimately improve treatment outcomes for patients."

"We are proud and excited to partner with Sirtex, mainly because it will provide access to personalized dosimetry for a large number of patients across the globe," said Andrew Nelson, chief executive oficer of MIM Software Inc. "The treatment of liver tumors requires a multi-disciplinary approach, so it's a natural evolution for companies like ours to partner to provide an even faster, higher level of support and resources to treatment teams."

In the United States, SIR-Spheres Y-90 resin microspheres received Premarket Approval (PMA) from the FDA and are indicated for the treatment of non-resectable metastatic liver tumors from primary colorectal cancer in combination with intrahepatic artery chemotherapy using floxuridine. SIR-Spheres Y-90 resin microspheres are approved for the treatment of inoperable liver tumors in Australia, the European Union, Argentina, Brazil, Canada and several countries in Asia, such as India and Singapore.

About Selective Internal Radiation Therapy (SIRT) using SIR-Spheres Y-90 resin microspheres

SIR-Spheres Y-90 resin microspheres is a prescription device for the treatment of inoperable liver tumors. SIRT is a minimally invasive treatment that delivers high doses of high-energy beta radiation directly to the tumors. SIRT is administered to patients by interventional radiologists and nuclear medicine physicians, who infuse millions of radioactive resin microspheres via a catheter into the liver arteries that supply blood to the tumors. By using the tumors' blood supply, the microspheres selectively target liver tumors with a dose of radiation that is up to 40 times higher than conventional radiotherapy, while sparing healthy tissue.

For more information: www.sirtex.com


Related Content

News | Artificial Intelligence

May 21, 2024 — According to a newly-published study of nearly 5,000 screening mammograms interpreted by an FDA-approved ...

Time May 21, 2024
arrow
News | Proton Therapy

May 21, 2024 — IBA, a world leader in particle accelerator technology, announced that it has signed a contract with the ...

Time May 21, 2024
arrow
News | Point-of-Care Ultrasound (POCUS)

May 20, 2024 — Exo (pronounced “echo”), a medical imaging software and devices company, announced the release of Exo ...

Time May 20, 2024
arrow
News | ASTRO

May 17, 2024 — Registration opens today for the American Society for Radiation Oncology's (ASTRO) 66th Annual Meeting ...

Time May 17, 2024
arrow
News | Cardiac Imaging

May 17, 2024 — The Cum Laude Award-Winning Online Poster presented during the 124th ARRS Annual Meeting found that the ...

Time May 17, 2024
arrow
News | Radiology Business

May 14, 2024 — University Hospitals (UH) and Siemens Healthineers announce a 10-year strategic alliance that builds on ...

Time May 14, 2024
arrow
News | Radiopharmaceuticals and Tracers

May 8, 2024 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of ...

Time May 08, 2024
arrow
News | RSNA

May 7, 2024 — The Radiological Society of North America (RSNA) and the Radiological and Diagnostic Imaging Society of ...

Time May 07, 2024
arrow
News | Magnetic Resonance Imaging (MRI)

May 7, 2024 — The Magna Cum Laude Award-Winning Online Poster presented during the 124th ARRS Annual Meeting showed a ...

Time May 07, 2024
arrow
News | ARRS

May 7, 2024 — The American Roentgen Ray Society (ARRS) announced that Philip Costello, MD, the 118th ARRS President and ...

Time May 07, 2024
arrow
Subscribe Now